Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
24,000.80
(
1.06%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
98.08
(
-3.11%
)
Bitcoin
74,058.00
(
1.72%
)
News Focus
News Focus
Post# of 257247
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122788
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 67956

Wednesday, 10/29/2008 9:40:49 PM

Wednesday, October 29, 2008 9:40:49 PM

Post# of 257247
GSK had an HCV polymerase inhibitor in phase-1 that was dropped in 2007.

>Wonder if they would buy vrtx?<

The $57M GSK is paying to get GNLB is barely more than round-off error.

GSK recently discontinued its share-buyback program to facilitate the financing of one or more large acquisitions.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now